Evidence map›Paper›PMID 42860425›Full record

ArticleNature communications2026

Genome-wide analysis of 439 mass spectrometry-based proteomic profiles in a population of 15,035 Scottish individuals.

Anne Richmond, Josephine A Robertson, Hannah M Smith, Robert F Hillary, Aleksej Zelezniak, Spyros Vernardis, Aleksandra D Chybowska, Arturas Grauslys, Jure Mur, Archie Campbell and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Anne Richmond *Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-9504-510X
Josephine A Robertson *Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-8142-8575
Hannah M Smith *Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Robert F Hillary *Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Aleksej ZelezniakMolecular Biology of Metabolism Laboratory, The Francis Crick Institute, London, UK.
Spyros VernardisMolecular Biology of Metabolism Laboratory, The Francis Crick Institute, London, UK.
Aleksandra D ChybowskaInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-1916-318X
Arturas GrauslysEliptica Limited, The London Cancer Hub, London, UK.
Jure MurInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Archie CampbellInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-0198-5078
Camilla DrakeInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.ORCID 0009-0003-0089-2571
Hannah GrantInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Poppy AdkinInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Matthew WhiteMolecular Biology of Metabolism Laboratory, The Francis Crick Institute, London, UK.
Charles BrigdenEliptica Limited, The London Cancer Hub, London, UK.
Christoph B MessnerMolecular Biology of Metabolism Laboratory, The Francis Crick Institute, London, UK.
David J PorteousInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Caroline HaywardInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-9405-9550
Andrew M McIntoshInstitute for Neurocience and Cardiovascular Research, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-0198-4588
Daniel L McCartneyInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Markus RalserMolecular Biology of Metabolism Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0001-9535-7413
Riccardo E MarioniInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. riccardo.marioni@ed.ac.uk.ORCID 0000-0003-4430-4260

Funding

Alzheimer's Society AS-PG-19b-010British Heart Foundation FS/IPBSRF/22/27042Wellcome Trust 104036/Z/14/ZWellcome Trust 108890/Z/15/ZWellcome Trust 218493/Z/19/ZWellcome Trust 220857/Z/20/ZWellcome Trust 221890/Z/20/ZWellcome Trust 319878/Z/24/Z
6 · The paper itself

Abstract

Understanding the genetic architecture of the circulating proteome can help determine if a protein is causally linked to disease. Previous large-scale genome-wide association studies of proteins have mostly been conducted on pre-defined, targeted subsets of the proteome, and have often concentrated on low-abundance proteins, many of which don't exert their main function in serum. Mass spectrometry-based proteomics facilitates the study of high-abundance proteins and their isoforms, focusing on proteins active in blood. In 15035 individuals from Generation Scotland, we perform genome-wide association studies of 439 highly abundant serum protein groups as identified and quantified by liquid chromatography tandem mass spectrometry. We identify 1553 independent SNP signals for 398 proteins (P < 1.2×10

Indexed as

Blood ProteinsGenome-Wide Association StudyProteomeProteomicsHumansMass SpectrometryMendelian Randomization AnalysisPolymorphism, Single NucleotideScotlandTandem Mass SpectrometryBlood ProteinsProteome

Identifiers

PMID42860425
PMCPMC13655163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.